Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - ALNYLAM PHARMACEUTICALS, INC. | alny-ex322_6.htm |
| EX-32.1 - EX-32.1 - ALNYLAM PHARMACEUTICALS, INC. | alny-ex321_7.htm |
| EX-31.2 - EX-31.2 - ALNYLAM PHARMACEUTICALS, INC. | alny-ex312_8.htm |
| EX-31.1 - EX-31.1 - ALNYLAM PHARMACEUTICALS, INC. | alny-ex311_9.htm |
| EX-21.1 - EX-21.1 - ALNYLAM PHARMACEUTICALS, INC. | alny-ex211_988.htm |
| EX-10.14 - EX-10.14 - ALNYLAM PHARMACEUTICALS, INC. | alny-ex1014_989.htm |
| 10-K - 10-K - ALNYLAM PHARMACEUTICALS, INC. | alny-10k_20161231.htm |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Forms S-8 (Nos. 333-190498, 333-127450, 333-116151, 333-148114, 333-157633, 333-165105, 333-172370 and 333-207251) of Alnylam Pharmaceuticals, Inc. of our report dated February 15, 2017 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 15, 2017